- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?
In a recent video interview from the American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin Lowentritt, MD discussed the challenges of conventional imaging in diagnosing prostate cancer recurrence and the potential of an emerging high affinity, radiohybrid prostate-specific membrane antigen/positron emission tomography (PSMA/PET) imaging agent.
Traditional imaging has limitations in the early detection of prostate cancer recurrence. Bone scintigraphy, computed axial tomography (CAT) and magnetic resonance imaging (MRI) “often are unable to detect small recurrences when they would be more responsive to salvage therapy,” noted Benjamin Lowentritt, M.D., in a recent video interview from the American Society for Radiation Oncology (ASTRO) Annual Meeting.
However, Dr. Lowentritt, the director of the Prostate Cancer Care Program at Chesapeake Urology, said the emergence of prostate-specific membrane antigen/positron emission tomography (PSMA/PET) imaging agents over the past year and a half has “truly transformed care” as they have allowed improved staging and detection of recurrent prostate cancer, facilitating more targeted use of therapies.
As a co-author on the phase III multicenter SPOTLIGHT trial, Dr. Lowentritt said the study findings demonstrated that the emerging PSMA/PET agent 18F-rhPSMA-7.3 (Blue Earth Diagnostics/Bracco Imaging) was a “strong performer across a variety of different clinical factors” in the detection of prostate cancer recurrence. According to the study of 389 patients, 18F-rhPSMA-7.3 had an overall majority read detection rate of 83 percent.
(Editor's note: For related articles, see "Study Suggests Shorter Duration of Radiation Therapy is Effective for High-Risk Prostate Cancer" or "FDA to Review Blue Earth Diagnostics' Emerging PSMA/PET Agent for Prostate Cancer.")
While emphasizing that there are currently no comparative trials of PSMA/PET imaging agents for detecting prostate cancer recurrence, Dr. Lowentritt said a possible advantage of 18F-rhPSMA-7.3 is the agent’s potential for less urinary excretion.
“We know this is a disease that often recurs in the pelvis so having a cleaner looking pelvis we would hope might allow this (agent) to have possibly a better ability to detect disease and more definitively detect disease in the pelvis,” added Dr. Lowentritt, president of the MidAtlantic Region of the American Urological Association.
For more insights from Dr. Lowentritt, watch the video below.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
